Avenue Therapeutics Stock (NASDAQ:ATXI)
Previous Close
$0.24
52W Range
$0.17 - $3.93
50D Avg
$0.24
200D Avg
$1.22
Market Cap
$765.34K
Avg Vol (3M)
$7.13K
Beta
-0.10
Div Yield
-
ATXI Company Profile
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.